Adenocyte Ltd
General Data
Reg Number
516302361
Sector
Medical Devices
Established
2020
No. of Employees
15
Stage
Initial Revenues
Additional Funding
0
Description
LINFU® utilizes a natural side effect of standard ultrasound microbubble contrast agents to increase by over 100X the number of ductal cells and intact ductal cell clusters that are naturally found in the pancreatic fluid sample
Technology
MedTech.
Targeted Customers
Oncologists.
Management personnel
Mark Rutenberg - CEO & Founder
Dan Adam - CTO
Scott Korman - CFO
Winning details
Route name
Winning year
R&D Program
R&D Program
2023
R&D Fund
R&D Fund
2024